Castle Creek Pharmaceuticals

castlecreekpharma.com

Castle Creek Pharma is a high growth biopharmaceutical company founded by an experienced team of pharmaceutical entrepreneurs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

NOVO NORDISK TO ACQUIRE FORMA THERAPEUTICS AND EXPAND PRESENCE IN SICKLE CELL DISEASE AND RARE BLOOD DISORDERS

Novo Nordisk | September 02, 2022

news image

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead developm...

Read More

Business Insights

LIGAND AND GSK EXPAND GLOBAL COLLABORATION AND LICENSE AGREEMENT

Ligand Pharmaceuticals | December 22, 2021

news image

Ligand Pharmaceuticals Incorporated announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline. The expansion will leverage Icagen’s ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevan...

Read More

Business Insights

LEXISNEXIS® REED TECH™ AND SCHLAFENDER HASE® ALLIANCE PROVIDES MUTUAL CUSTOMER BENEFITS FOR PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES

LexisNexis Reed Tech | April 27, 2022

news image

Reed Technology and Information Services Inc. a leading provider of data management and analytics solutions for the life sciences industry, announced an alliance with Schlafender Hase®, the market leader for intelligent, automated proofreading software and services for regulated industries. Current and prospective customers of both companies can leverage exclusive benefits as part of this new alliance ecosystem. Pharmaceutical labelers who have regulatory deadlines for US FDA can benefit fro...

Read More

Business Insights

AVIDIEN TECHNOLOGIES RECEIVES $4M INVESTMENT FROM BROADOAK CAPITAL PARTNERS

Avidien Technologies | February 02, 2022

news image

Avidien announced a new financing round of $4M from BroadOak Capital Partners. The investment will help Avidien expand its product roadmap, scale commercial production, and better serve research and pharmaceutical clients. "The partnership with BroadOak is exciting and ushers in the next phase for Avidien by creating the opportunity to quickly scale up the business with investments in new products, sales, marketing, and manufacturing." ...

Read More
news image

Business Insights

NOVO NORDISK TO ACQUIRE FORMA THERAPEUTICS AND EXPAND PRESENCE IN SICKLE CELL DISEASE AND RARE BLOOD DISORDERS

Novo Nordisk | September 02, 2022

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead developm...

Read More
news image

Business Insights

LIGAND AND GSK EXPAND GLOBAL COLLABORATION AND LICENSE AGREEMENT

Ligand Pharmaceuticals | December 22, 2021

Ligand Pharmaceuticals Incorporated announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline. The expansion will leverage Icagen’s ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevan...

Read More
news image

Business Insights

LEXISNEXIS® REED TECH™ AND SCHLAFENDER HASE® ALLIANCE PROVIDES MUTUAL CUSTOMER BENEFITS FOR PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES

LexisNexis Reed Tech | April 27, 2022

Reed Technology and Information Services Inc. a leading provider of data management and analytics solutions for the life sciences industry, announced an alliance with Schlafender Hase®, the market leader for intelligent, automated proofreading software and services for regulated industries. Current and prospective customers of both companies can leverage exclusive benefits as part of this new alliance ecosystem. Pharmaceutical labelers who have regulatory deadlines for US FDA can benefit fro...

Read More
news image

Business Insights

AVIDIEN TECHNOLOGIES RECEIVES $4M INVESTMENT FROM BROADOAK CAPITAL PARTNERS

Avidien Technologies | February 02, 2022

Avidien announced a new financing round of $4M from BroadOak Capital Partners. The investment will help Avidien expand its product roadmap, scale commercial production, and better serve research and pharmaceutical clients. "The partnership with BroadOak is exciting and ushers in the next phase for Avidien by creating the opportunity to quickly scale up the business with investments in new products, sales, marketing, and manufacturing." ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us